Diagnostic Utility of Expression Pattern of S100/Mammaglobin/SOX10/DOG 1 Immunohistochemistry in Differentiation of Secretory and Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis
View abstract on PubMed
Summary
This summary is machine-generated.Secretory carcinoma (SC) diagnosis is improved using combined S100/Mammaglobin/SOX10/DOG1 immunohistochemistry. This method reliably distinguishes SC from acinic cell carcinoma (AciCC), aiding accurate patient classification.
Area Of Science
- Oncology
- Pathology
- Genetics
Background
- Secretory carcinoma (SC) is a distinct entity from acinic cell carcinoma (AciCC), often characterized by the ETV6-NTRK3 gene fusion.
- Distinguishing SC from AciCC can be challenging due to overlapping features and genetic diversity.
Purpose Of The Study
- To evaluate the diagnostic utility of combined immunohistochemical markers S100, Mammaglobin, SOX10, and DOG1 in differentiating SC from AciCC.
- To assess the sensitivity and specificity of this combined marker panel.
Main Methods
- A systematic review of electronic databases (MEDLINE, PubMed, Google Scholar, Scopus, Web of Science) was conducted.
- Eligible articles involving SC and AciCC with S100/Mammaglobin/SOX10/DOG1 immunohistochemistry were analyzed.
- Predominant expression patterns, predictive values, sensitivity, and specificity were extracted.
Main Results
- Fourteen articles were analyzed, revealing a predominant S100+/Mammaglobin+/SOX10+/DOG1- immunostaining pattern in SC, including those with ETV6-NTRK3 and other gene fusions (RET, MET, MAML3).
- The combined marker panel demonstrated 98.4% sensitivity and 86.1% specificity in distinguishing SC from AciCC.
Conclusions
- Combined immunohistochemical staining for S100, Mammaglobin, SOX10, and DOG1 is a reliable method for differentiating secretory carcinoma from acinic cell carcinoma.
- This approach offers a valuable tool for accurate histological diagnosis in challenging cases.

